Clinical Research Directory
Browse clinical research sites, groups, and studies.
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
Sponsor: Peking University People's Hospital
Summary
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.
Key Details
Gender
FEMALE
Age Range
Any - 45 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2024-07
Completion Date
2028-10
Last Updated
2024-07-16
Healthy Volunteers
No
Interventions
Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.